Ensuring Access to Essential Drugs Act
Summary
HR1922 is an early-stage bill referred to committee with no market impact. It would exempt certain orally administered brand-name drugs from Medicare Part D rebate obligations, but no hearings, votes, or further action have occurred since introduction on 2025-03-06.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1922 is in the earliest legislative stage with no momentum.
- 2.The exemption applies only to a narrow subset of drugs with a specific CMS reclassification — no affected drugs or companies are identifiable from the bill text.
- 3.No immediate market impact; the bill is purely procedural at this point.
Market Implications
No market implications at this stage. The bill does not name any companies, authorize spending, or create a clear revenue mechanism for any publicly traded entity. Retail investors should not adjust positions based on this bill alone.
Full Analysis
- HR1922, the 'Ensuring Access to Essential Drugs Act,' was introduced on March 6, 2025 by Rep. Garbarino (R-NY) with two cosponsors. It has been referred to both the Energy and Commerce and Ways and Means Committees. No further actions have occurred. 2) The bill does not authorize or appropriate any funding. It modifies the Medicare Part D Manufacturer Discount Program to exempt specific orally administered brand-name drugs that have been reclassified as noninnovator multiple source drugs under Medicaid. This is a regulatory exemption, not a spending bill. 3) No specific publicly traded companies are directly named in the bill text. The exemption would apply to a narrow, undefined set of drugs requiring a CMS exception. Without knowing which drugs or manufacturers hold such exceptions, no ticker-level analysis is possible. 4) The bill has zero legislative velocity — two committee referrals on the same day and no actions since. No companion bill in the Senate. 5) Next steps would require committee hearings, markup, floor votes in both chambers, and presidential action. Given the early stage and narrow scope, meaningful market impact is years away if it advances at all.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →